Rock Creek Pharmaceuticals, Inc. (NASDAQ:STSI)

CAPS Rating: 1 out of 5

The Company is engaged in developing, implementing and licensing scientific technology for the curing of tobacco and also manufactures, markets and develops very low-nitrosamine smokeless tobacco products and selling of discount cigarettes.

Results 1 - 20 of 58 : 1 2 3 Next »

Recs

0
Member Avatar pchop123 (78.31) Submitted: 4/15/2014 8:19:45 PM : Outperform Start Price: $0.78 STSI Score: -4.91

likely to soon rebound

Recs

1
Member Avatar zzlangerhans (99.73) Submitted: 4/1/2014 9:18:24 PM : Outperform Start Price: $0.78 STSI Score: -3.20

It must be a strange feeling to still own stock in Star Scientific. The longs used to be one of the more strident cults in biopharma, tag teaming to attack critics such as myself for pointing out the obvious scam-like qualities of the company. These days though, it's hard to arouse a sluggish whimper from bruised Star-fish as the stock free-falls into the pennies. Is this the death spiral? If so, I'll have my first losing score on the stock, but I suspect otherwise. Lack of revenue growth from the Anatabloc "supplement" and an FDA warning letter has shown new management that their only route to maintaining the scam is to pretend to be developing a pharmaceutical. Towards that end, they will be submitting an IND for Anatabloc, in all likelihood this quarter, for the purported indication of Alzheimer's. They have suspended the ongoing clinical trial pending filing of the IND, having enrolled 62 patients. Don't ask me how they were able to run a clinical trial without having submitted the IND, or why they now have to suspend it. In the meantime, they will be dragging their heels as long as possible before releasing results of the Anatabloc facial creme study. They've already telegraphed the failure of the trial in their recent 10K filing, where they state that an early analysis of the data indicates that both the study drug and placebo had a strong beneficial effect. The translation is that you might as well use a placebo.

Yes, I did mean to enter a green thumb here. The stock has been dripping downward for a few straight sessions, the bullsh!t biopharma bubble is not done yet, people will misinterpret the submission of the Anatabloc IND as a positive development, they will get excited over the mention of the word Alzheimer's, they will buy silly company spin about the failed facial creme study. At least one and probably more of these elements will contribute to a rebound at some point. Hopefully it won't come too late to perpetuate my perfect record on Star Scientific.

Recs

0
Member Avatar Shankapotamus (30.22) Submitted: 2/19/2014 7:04:03 PM : Underperform Start Price: $0.76 STSI Score: +2.89

Overvalued

Recs

0
Member Avatar loangolfer (< 20) Submitted: 2/13/2014 8:50:59 AM : Outperform Start Price: $0.67 STSI Score: +8.86

watch list says so

Recs

0
Member Avatar TSIF (99.96) Submitted: 2/3/2014 2:10:24 PM : Underperform Start Price: $0.74 STSI Score: +2.99

Similar to ZZ, Star/AKA Rock Creek Pharmacuticals, Inc has risen from cold ashes so many times, that I hesitated adding a downthumb as it dropped near $1.00. I sensed something may be different this time, but it's hard to think reality can eventually set in after a decade of fiction. STSI, has hit the $1.00 share price three times sincde 2003 and rebounded back to near $5.00. If one played it like an accordian, they could have a Million bucks and a few thousand CAPS points,all from fantasy. ZZ played it 15 times down, but is edging for the rebound, and it's hard not to try it.

Overall, if he or I downthumb it and pitch it, we get used in a quote in a mini-article and the pumpers, dreamers, and zombies come out of the dark corners and reign hate on us in multiple forms. Jealous, shorts, stupid, anti-people who need the product, etc. In most cases my call is purely metrics and even assumes that STSI did hit some kind of home run. Market cap has remained incredible under any successful scenerio.

That Anatabloc can cure/alleviate 100 different ailments, (list is growing, I stopped counting), should be enough to warn most away. If it helps some with joint pain, or another malady then great. The only documented study is that it helped mice in extreme doses, although I think it was probably the placebo effect. Those mice are tough to guage.

Some suggest that the issues with the Governor of Virginia is overblown. After all, he was feeling better from his free Anatabloc samples, (or was it the STSI gifted Rolex watch making him better, metal on the wrist can have some strange effects). He only wanted the state to do studies so the dietary supplement could be rebranded for medical use, (or to fulfill any of the claims the FDA chided STSI from making). He merely wanted the State Employees to be part of a scientific study, paid for by State taxpayers. After all, they would all feel better, work harder, lower state health costs, etc. .... a win-win for everyone.

I suspect this is the last change to get in above $0.50 here on CAPS until the split. Fortunatley for STSI the outstanding share count can probably reverse split several times. They issued $80 Million dollars worth in the last three years, so there is plenty out there. The current Antabloc sales won't pay for the private jet that they let the Governor use, assuming it stays on the market, so they will need to do something creative.

Who knows another smoking derivative may be in the works an the $1.00 to $5.00 cycle on 1/10th the current shares may strike again.

Recs

0
Member Avatar HoldThatWinner (33.33) Submitted: 4/4/2013 2:46:08 PM : Outperform Start Price: $1.33 STSI Score: -63.18

A lot of red thumbs. I'll play the other direction down here.

Recs

0
Member Avatar r3ram (< 20) Submitted: 1/10/2013 2:20:41 PM : Outperform Start Price: $2.63 STSI Score: -98.74

If the Advertising gears up to inform public. Articles placed in the AARP magazine, Advertise in Medical Journals, have GNC share cost of advertising.

Partner with other Medical Journals to write the story.

Tell the Story of successes in trials, user forums,

Recs

1
Member Avatar Joytotheinvstmnt (< 20) Submitted: 12/6/2012 4:04:28 PM : Outperform Start Price: $3.11 STSI Score: -106.66

I have been using Anatabloc personally since January 2012 for treatment of my asthma, which was getting so bad, my Advair 500 was no longer providing relief, & Ventlolin 200 was next to useless. I have now not required Ventolin for months & have cut back to Advair 250, which I am considering ceasing altogether. I can't say how well it treats any other conditions, but it is worth every cent just for its asthma treatment.

Recs

0
Member Avatar Imhilion (93.25) Submitted: 11/26/2012 12:13:02 PM : Underperform Start Price: $2.54 STSI Score: +103.03

P&D

Recs

2
Member Avatar KT3386 (< 20) Submitted: 9/3/2012 4:02:51 AM : Outperform Start Price: $3.80 STSI Score: -112.42

If the substance they are experimenting is really decrease the chronic inflammation , then we are talking about huge gains, even a takeover from a big pharma company.If...

Recs

3
Member Avatar XMFWill (< 20) Submitted: 6/11/2012 3:33:24 PM : Outperform Start Price: $4.01 STSI Score: -122.53

One of the best, most undervalued products on the market (Anatabloc), which reduces inflammation and is making huge inroads in the medical field. Could see massive gains.

Recs

2
Member Avatar mirwin52 (< 20) Submitted: 2/29/2012 10:42:16 AM : Outperform Start Price: $4.01 STSI Score: -117.04

game changer. try Anatabloc for yourself.

Recs

1
Member Avatar texans2 (< 20) Submitted: 2/27/2012 1:33:06 PM : Outperform Start Price: $4.05 STSI Score: -117.34

Hype. So many are hyping Anatabine as a miracle cure and early anecdotal evidence suggests there is reason for optimism on the success of the product by Star Scientific. I'm more bullish on it's anti-aging properties though that will take much longer to affect PPS.

Recs

2
Member Avatar zCreator (93.85) Submitted: 2/23/2012 1:29:45 AM : Underperform Start Price: $3.84 STSI Score: +117.56

I could be a bit early on the underperform.

Recs

3
Member Avatar wceb (< 20) Submitted: 2/7/2012 12:03:31 PM : Outperform Start Price: $3.12 STSI Score: -114.38

STAR holds patents on all medical uses of anatabine, a non-nicotine substance in tobacco, peppers, tomatoes. . . Research from Roskamp Institute shows it is better than Lipitor in reducing general inflammation marker C-reactive protein. Such inflammation is found in: arteriosclerosis, arthritis, Alzheimer's, thyroiditis, . . . Anatabine, a neutraceutical, now selling online at www.anatabloc.com and at General Nutrition stores. Many testimonials, and medical studies in humans, confirms activity, deeper research due out soon. Dr Michael Mullen, a co-discoverer of Alzheimer's plaques, and internationally famous researcher, was asked if he would recommend giving anatabine to a relative with developing sysmptoms: he said "Yes."
http://www.mullanalzheimer.com/category/mike-mullan-alzheimer/ for Jan 2012 addl details

Recs

2
Member Avatar seriously101 (< 20) Submitted: 2/6/2012 6:21:34 PM : Outperform Start Price: $3.07 STSI Score: -114.49

Anatablock and RJR settlement

Recs

1
Member Avatar keithgray1 (< 20) Submitted: 2/6/2012 2:04:12 PM : Outperform Start Price: $2.99 STSI Score: -113.80

Anatabloc

Recs

3
Member Avatar NobHillSF (< 20) Submitted: 2/6/2012 1:50:58 PM : Outperform Start Price: $2.98 STSI Score: -113.77

Feb. 9th when RAI has to release it's legal liability to shareholders will see this stock jump. Institutions adding and short sellers at the end of their rope. Hard to borrow shares, amount available has dropped drastically- classic short squeeze in the works. This doesn't include even the upside potential of Anatabloc- a name you will hear over and over again as studies come out.

Recs

1
Member Avatar taraowner (< 20) Submitted: 2/6/2012 1:34:22 PM : Outperform Start Price: $2.98 STSI Score: -113.63

Company has new inflammatory product lines based on Anatabine substance getting excellent results as OTC nutritional product. Chew tobacco lines should be sold off and Patents have been validated. Don't know why always comparing company to RJR or MO guess writers don't do DD. Take a look and see if I am wrong.

Recs

1
Member Avatar jmu1986 (< 20) Submitted: 1/26/2012 3:10:38 AM : Outperform Start Price: $2.19 STSI Score: -105.74

They will have outstanding results from the Flint study to be released soon

Results 1 - 20 of 58 : 1 2 3 Next »

Featured Broker Partners


Advertisement